<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "bevacizumab inj VIAL">
<dose><value>5</value>
<value>7.5</value>
<value>10</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>bevacizumab inj VIAL</value>
</drugname><strength><value>25 mg/mL</value>
</strength><frequency><value>ONCE</value>
</frequency><instruction><value>DAY 1 of 14. Dilute dose in 100 mL 0.9% sodium chloride and administer over 10 minutes. (Maximum rate of administration is 0.5 mg/kg/minute.)</value>
<value>DAY 1 of 21. Dilute dose in 100 mL 0.9% sodium chloride and administer over 15 minutes. (Maximum rate of administration is 0.5 mg/kg/minute.)</value>
<value>DAY 1 of 14. Dilute dose in 100 mL 0.9% sodium chloride and administer over 20 minutes. (Maximum rate of administration is 0.5 mg/kg/minute.)</value>
</instruction><volume><value>16 mL</value>
<value>4 mL</value>
</volume><units><value>mg/kg</value>
</units><additionalnotes><value>For monitoring / administration information, refer to CancerControl Alberta Bevacizumab (Avastin) Administration Guidelines.</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3345</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary with Restrictions, Usage guidelines.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose></maximumprndose><din><value>02270994</value>
</din></drug>